Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal cell therapy for severe COVID-19 respiratory syndrome
RBR-3fz9yrCompleted
- Sponsor
- Paulo Roberto Slud Brofman
- Start
- Jun 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Trial of MSV alogénicas in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Paulo Roberto Slud Brofman. Started Jun 2020; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on RBR-3fz9yr.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3fz9yr.